Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00239564 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
A Phase 1 study of Idiopathic Parkinson´s Disease, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT00239564: Completed Phase 1 study of Idiopathic Parkinson´s Disease, sponsored by Impax Laboratories.
NCT00239564 is a Phase 1 study of Idiopathic Parkinson´s Disease that has completed, run by Impax Laboratories. The registered enrollment target is 12 participants, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00239564, a Phase 1 study of Idiopathic Parkinson´s Disease, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release tablets.
Conditions Studied
Interventions
- DRUG IPX054 200 mg
- DRUG IPX054 100 mg
- DRUG IPX054 150 mg
- DRUG IPX054 250 mg
- DRUG IPX054 300 mg
Study Locations (2)
California
- Site 101 - Sunnyvale
Kansas
- Site 102 - Lawrence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-12 |
| Phase | Phase 1 |
What the finished NCT00239564 record still lists
NCT00239564 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 218-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 5 interventions - of which IPX054 200 mg is the first listed.
NCT00239564 reports a single indexed study location in California, Kansas.
Frequently Asked Questions
What is clinical trial NCT00239564 about?
NCT00239564 is a clinical study titled "Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease". The objective is to compare the pharmacokinetics and pharmacodynamics of IPX054 and carbidopa-levodopa immediate-release tablets in subjects with idiopathic Parkinson's disease who are currently being treated with a stable regimen of carbidopa-levodopa immediate-release tablets.
What is the current status of trial NCT00239564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2005-10. Estimated completion is 2007-12.
What conditions does trial NCT00239564 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease.
What interventions are being tested in trial NCT00239564?
The interventions under investigation include: IPX054 200 mg (DRUG), IPX054 100 mg (DRUG), IPX054 150 mg (DRUG), IPX054 250 mg (DRUG), IPX054 300 mg (DRUG).
Who is sponsoring clinical trial NCT00239564?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00239564 being conducted?
This trial has 2 study locations across California, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
RECRUITING · Phase 1
-
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Infusion of Apomorphine: Long-term Safety Study
ACTIVE NOT RECRUITING · Phase 3
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia